The use of biodiversity as source of new chemical entities against defined molecular targets for treatment of malaria, tuberculosis, and T-cell mediated diseases - A Review

Memorias do Instituto Oswaldo Cruz

Volumn 100, Issue 6, 2005, Pages 475-506

  Basso, Luiz Augusto ^a   Pereira Da Silva, Luiz Hildebrando ^b   Fett Neto, Arthur Germano ^c   De Azevedo Jr , Walter Filgueira ^a   Moreira, Ícaro De Souza ^d   Palma, Mário Sérgio ^e   Calixto, João Batista ^f   Astolfi Filho, Spartaco ^g   Ribeiro Dos Santos, Ricardo ^h   Pereira Soares, Milena Botelho ^h   Santos, Diógenes Santiago ^g  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Centro de Pesquisa em Medicina Tropical   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^e SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^f FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^g FEDERAL UNIVERSITY OF AMAZONAS   (Brazil)

^h INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Apicomplexan; Biodiversity; Defined molecular targets; T cell mediated diseases; Tuberculosis

Indexed keywords

ARAUCARIA;

EID: 27744521577     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762005000600001     Document Type: Review

References (246)

1. Altmann KH 2001. Microtubule-stabilizing agents: a growing class of important anticancer drugs. Curr Opin Chem Biol 5: 424-431.
2. Amenta R, Camarda L, Di Stefano V, Lentini F, Venza F 2000. Traditional medicine as a source of new therapeutic agents against psoriasis. Fitoterapia 71: S13-20.
3. Andrade-Neto VF, Brandão MG, Stehmann JR, Oliveira LA, Krettli AU 2003. Antimalarial activity of Cinchona-like plants used to treat fever and malaria in Brazil. J Ethnopharmacol 87: 253-256.
4. Andrade-Neto VF, Brandão MG, Oliveira FQ, Casali VW, Njaine B, Zalis MG, Oliveira LA, Krettli AU 2004. Antimalarial activity of Bidens pilosa L. (Asteraceae) ethanol extracts from wild plants collected in various localities or plants cultivated in humus soil. Phytother Res 18: 634-639.
5. Andries K, Verhasselt P, Guillemont J, Göhlmann HWH, Neefs JM, Winkler H, Gestel JV, Timmerman P, Zhu M, Lee E, Williams P, Chaffoy D, Huitric E, Hoffher S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227.
6. Arpaia E, Benveniste P, Di Cristofano A, GuY, Dalal I, Kelly S, Hershfield M, Pandolfi PP, Roifman CM, Cohen A 2000. Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice. J Exp Med 191: 2197-2208.
7. Atlung T, Ingmer H 1997. H-NS: a modulator of environmentally regulated gene expression. Mol Microbiol 24: 7-17.
8. Avarbock D, Salem J, Li L, Wang Z, Rubin H 1999. Cloning and characterization of a bifunctional RelA/SpoT homologue from Mycobacterium tuberculosis. Gene 233: 261-269.
9. Azevedo Jr WF, Canduri F, Oliveira JS, Basso LA, Palma MS, Pereira JH, Santos DS 2002. Molecular model of shikimate kinase from Mycobacterium tuberculosis. Biochem Biophys Res Commun 5: 142-148.
10. Azevedo Jr WF, Canduri F, Santos DM, Silva RG, Oliveira JS, Carvalho LPS, Basso LA, Mendes MA, Palma MS, Santos DS 2003a. Crystal structure of human purine nucleoside phosphorylase at 2.3 Å resolution. Biochem Biophys Res Commun 308: 545-552.
11. Azevedo Jr WF, Canduri F, Santos DM, Pereira JH, Dias MVB, Silva RG, Mendes MA, Basso LA, Palma MS, Santos DS 2003b. Structural basis for inhibition of human PNP by Immucillin-H. Biochem Biophys Res Commun 309: 917-922.
12. Azevedo Jr WF, Canduri F, Santos DM, Pereira JH, Dias MVB, Silva RG, Mendes MA, Basso LA, Palma MS, Santos DS 2003c. Crystal structure of human PNP complexed with guanine. Biochem Biophys Res Commun 312: 767-772.
13. Bahl A, Brunk B, Coppel RL, Crabtree J, Diskin SJ, Fraunholz MJ, Grant GR, Gupta D, Huestis RL, Kissinger JC, Labo P, Li L, McWeeney SK, Milgram AJ, Roos DS, Schug J, Stoeckert CJJr 2002. PlasmoDB: the Plasmodium genome resource. An integrated database providing tools for accessing, analyzing and mapping expression and sequence data (both finished and unfinished). Nucleic Acids Res 30: 87-90.
14. Banerjee A, Dubnau E, Quémard A, Balasubramanian V, Um KS, Wilson T, Collins D, de Lisle G, Jacobs Jr WR1994. inhA, a Gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263: 227-230.
15. Banerjee A, Sugantino M, Sacchettini JC, Jacobs WRJr 1998. The mabA gene from the inhA operon of Mycobacterium tuberculosis encodes a 3-ketoacyl reductase that fails to confer isoniazid resistance. Microbiology 144: 2697-2704.
16. Bannister LH, Hopkins JM, Fowler RE, Krishna S, Mitchel GH 2000. A brief illustrated guide to the ultrastructure of Plasmodium falciparum asexual blood stages. Parasitol Today 16: 427-433.
17. Bantia S, Montgomery JA, Johnson HG, Walsh GM 1996. In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP. Immunopharmacology 35: 53-63.
18. Basso LA, Blanchard JS 1998. Resistance to antitubercular drugs. Adv Exp Med Biol 456: 115-144.
19. Basso LA, Santos DS 2005. Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis - an update. Medicinal Chemistry Reviews - Online (Ref. No. MCRO/03/INV).
20. Basso LA, Santos DS, Shi W, Furneaux RH, Tyler PC, Schramm VL, Blanchard JS 2001. Purine nucleoside phosphorylase from Mycobacterium tuberculosis. Analysis of inhibition by a transition-state analogue and dissection by parts. Biochemistry 40: 8196-8203.
21. Basso LA, Zheng R, Blanchard JS 1996. Kinetics of inactivation of WT and C243S mutant of Mycobacterium tuberculosis enoyl reductase by activated isoniazid. J Am Chem Soc 118: 11301-11302.
22. Basso LA, Zheng R, Musser JM, Jacobs Jr W, Blanchard JS 1998. Mechanism of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J Infect Dis 178: 769-775.
23. Bekal S, Niblack TL, Lambert KN 2003. A chorismate mutase from the soybean cyst nematode Heterodera glycines shows polymorphisms that correlate with virulence. Mol Plant Microbe Interact 16: 439-446.
24. Bennett Jr LL, Allan PW, Noker PE, Rose LM, Niwas S, Montgomery JA, Erion MD 1993. Purine nucleoside phosphorylase inhibitors: biochemical and pharmacological studies with 9-benzyl-9-deazaguanine and related compounds. J Pharmacol Exp Ther 266: 707-14.
25. Bentley R 1990. The shikimate pathway - A metabolic tree with many branches. Crit Rev Biochem Mol Biol 25: 307-384.
26. Berman PA, Human L, Freese JA 1991. Xanthine oxidase inhibits growth of Plasmodium falciparum in human erythrocytes in vitro. J Clin Invest 88: 1848-55.
27. Berry JP, McFerren MA, Rodriguez E 1995. Zoopharmacognosy: a "biorational" strategy for phytochemical prospecting. In DL Gustine, H Flores (eds), Phytochemicals and Health, ASPP, Rockville, p. 165-178.
28. Blanchard JS 1996. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Annu Rev Biochem 65: 215-239.
29. Bloch K 1975. Fatty acid synthases from Mycobacterium phlei. Methods Enzymol 35: 84-90.
30. Blower SM, Chou T 2004. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat Med 10: 1111-1116.
31. Both FL, Kerber VA, Henriques AT, Elisabetsky E 2002. Analgesic properties of umbellatine from Psychotria umbellata. Pharm Biol 40: 336-341.
32. Breman JG, Alilio MS, Mills A 2004. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am J Trop Med Hyg 71: 1-15.
33. Brennan PJ 2003. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis 83: 91-97.
34. Brennan PJ, Nikaido H 1995. The envelope of mycobacteria. Annu Rev Biochem 64: 29-63.
35. Brindley DN, Matsumura S, Block K 1969. Mycobacterium phlei fatty acid synthase - A bacterial multienzyme complex. Nature 224: 666-669.
36. Brohm D, Metzger S, Bhargava A, Muller O, Lieb F, Waldmann H 2002. Natural products are biologically validated starting points in structural space for compound library development: solid-phase synthesis of dysidiolide-derived phosphatase inhibitors. Angew Chem Int Ed Engl 41: 307-311.
37. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL 1998. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54: 905-921.
38. Burke MD, Schreiber SL 2004. A planning strategy for diversity oriented synthesis. Angew Chem Int Ed 43: 46-58.
39. Butler MS 2004. The role of natural product chemistry in drug discovery. J Nat Prod 67: 2141-2153.
40. Calhoun DH, Bonner CA, Gu W, Xie G, Jensen RA 2001. The emerging periplasm-localized subclass of AroQ chorismate mutases, exemplified by those from Salmonella typhimurium and Pseudomonas aeruginosa. Genome Biol. 2: 003010-003016.
41. Campanale N, Nickel C, Daubenberger CA, Wehlan DA, Gorman JJ, Klonis N, Becker K, Tilley L 2003. Identification and characterization of heme-interacting proteins in the malaria parasite, Plasmodium falciparum. J Biol Chem 278: 27354-27361.
42. Canduri F, Azevedo Jr WF2005. Structural basis for interaction of inhibitors with Cyclin-Dependent Kinase 2. Current Computer-Aided Drug Design 1: 53-64.
43. Canduri F, Fadel V, Dias MV, Basso LA, Palma MS, Santos DS, Azevedo Jr WF 2005a. Crystal structure of human PNP complexed with hypoxanthine and sulfate. Biochem Biophys Res Commun 326: 335-338.
44. Canduri F, Santos DM. Silva RG, Mendes MA, Basso LA, Palmar MS, Azevedo Jr WF, Santos DS 2004. Structures of human purine nucleoside phosphorylase complexed with inosine and ddl. Biochem Biophys Res Commun 313: 907-914.
45. Canduri F, Silva RG, Santos DM, Palma MS, Basso LA, Santos DS, Azevedo Jr WF 2005b. Structure of human PNP complexed with ligands. Acta Crystallogr D Biol Crystallogr 61: 856-862.
46. Cashel M, Gentry DR, Hernandez VJ, Vinella D 1996. The stringent response. In FC Neidhardt, Escherichia coli and Salmonella: Cellular and Molecular Biology, ASM Press, Washington, p. 1458-1496.
47. Chern JW, Lee HY, Chen CS. Nucleosides 1993. 5. Synthesis of guanine and formycin B derivatives as potential inhibitors of purine nucleoside phosphorylase. J Med Chem 36: 1024-1031.
48. Clardy J, Walsh C 2004. Lessons from natural molecules. Nature 432: 829-837.
49. Clements MO, Eriksson S, Thompson A, Lucchini S, Hinton JCD, Normark S, Rhen M 2002. Polynucleotide phosphorylase is a global regulator of virulence and persistency in Salmonella enterica. Proc Natl Acad Sci USA 99: 8784-8789.
50. Coggins JR, Abell C, Evans LB, Frederickson M, Robinson DA, Roszak AW, Lapthorn AP 2003. Experiences with the shikimate-pathway enzymes as targets for rational drug design. Biochem Soc Trans 31: 548-551.
51. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream M-A, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537-544.
52. Cooper MA 2002. Optical biosensors in drug discovery. Nature Rev Drug Discov 1: 515-528.
53. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C 2003. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163: 1009-1021.
54. Cragg GM, Boyd MR, Grever MR, Schepartz SA 1995. Pharmaceutical prospecting and the potential for pharmaceutical crops - Natural product drug discovery at the United States National Cancer Institute. AnnMissouri Bot Gard 82: 47-53.
55. Cronan JE, Rock CO 1996. Biosynthesis of membrane lipids. In FC Neidhardt, Escherichia coli and Salmonella: Cellular and Molecular Biology, ASM Press, Washington, p. 612-636.
56. de Voos JJ, Rutter K, Schroder BG, Su H, Zhu Y, Barry CEIII 2000. The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages. Proc Natl Acad Sci USA 97: 1252-1257.
57. DeBarber A, Mdluli K, Bosman M, Bekker L-G, Barry CEIII 2000. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc Natl Acad Sci USA 97: 9677-9682.
58. Dessen A, Quémard A, Blanchard JS, Jacobs WRJr, Sacchettini JC 1995. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 267: 1638-1641.
59. Dias MVB, Ely F, Canduri F, Pereira JH, Frazzon J, Basso LA, Palma MS, Azevedo WFJr, Santos DS 2004. Crystallization and preliminary X-ray crystallographic analysis of chorismate synthase from Mycobacterium tuberculosis. Acta Crystallogr D Biol Crystallogr 60: 2003-2005.
60. Dieckman A, Jung A 1986. Mechanisms of sulfadoxine resistance in Plasmodium falciparum. Mol Biochem Parasitol 19: 143-147.
61. Dobson CM 2004. Chemical space in biology. Nature 432: 824-828.
62. Dorman CJ 2004. H-NS: a universal regulator for a dynamic genome. Nat Rev Microbiol 2: 391-400.
63. Dosselaere F, Vanderleyden J 2001. A metabolic node in action: chorismate-utilizing enzymes in microorganisms. Crit Rev Microbiol 27: 75-131.
64. Duncan K 2003. Progress in TB drug development and what is still needed. Tuberculosis 83: 201-207.
65. α: Semisynthetic glycopeptides with potent activity against gram-positive bacteria. J Med Chem 47: 3487-3490.
66. Dutt AK, Stead W 1994. The treatment of tuberculosis. Dis Month 43: 247-274.
67. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC 1999. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 282: 677-686.
68. Ealick SE, Babu YS, Bugg CE, Erion MD, Guida WC, Montgomery JA, Secrist JAIII 1991. Application of crystallographic and modelling methods in the design of purine nucleoside phosphorylase inhibitor. Proc Natl Acad USA 91: 11540-11544.
69. Ealick SE, Rule SA, Carter DC, Greenhough TJ, Babu YS, Cook WJ, Habash J, Helliwell JR, Stoeckler JD, Parks REJr, Chen SF, Bugg CE 1990. Three-dimensional structure of human erythrocytic purine nucleoside phosphorylase at 3.2 Å resolution. J Biol Chem 265: 1812-1820.
70. Elisabetsky E, Amador TA, Leal M, Nunes DS 1997. Merging ethnopharmacology with chemotaxonomy: an approach to unveil bioactive natural products. The case of Psychotria alkaloids as potential analgesics. Ci Cul 49: 378-385.
71. Espinal MA 2003. The global situation of MDR-TB. Tuberculosis 83: 44-51.
72. Falconi M, Colonna B, Prosseda G, Micheli G, Gualerzi CO 1998. Thermoregulation of Shigella and Escherichia coli EEIEC pathogenicity. A temperature-dependent structural transition of DNA modulates accessibility of virF promoter to transcriptional repressor H-NS. Embo J 17: 7033-7043.
73. Feher M, Schmidt JM 2003. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci 43: 218-227.
74. Ferri MG 1980. Vegetação Brasileira (Brazilian Vegetation), Itatiaia/USP, São Paulo, 157 pp.
75. Fett-Neto AG, Aoyagi H, Tanaka H, Dicosmo F 2004. Antitumor Agents: Taxol and Taxane Production by Yew Cell Culture. In RA Myers, Encyclopedia of Molecular Cell Biology and Molecular Medicine, Wiley-VCH, Weinheim, p. 415-438.
76. Fitzpatrick T, Ricken S, Lanzer M, Amrhein N, Macheroux P, Kappes B 2001. Subcellular localization and characterization of chorismate synthase in the apicomplexan Plasmodium falciparum. Mol Microbiol 4: 65-75.
77. Franzon JH, Santos DS 2004. A role for histone-like protein H1 (H-NS) in the regulation of hemolysin expression by Serratia marcescens. Braz J Med Biol Res 37: 1763-1769.
78. Fritz-Wolf K, Becker A, Rahlfs S, Harwaldt P, Schirmer RH, Kabsch W 2003. X-ray structure of glutathione S-transferase from the malarial parasite Plasmodium falciparum. Proc Natl Acad Sci USA 100: 13821-13826.
79. Frostell-Karlsson A, Remaeus A, Roos H, Andersson K, Borg P, Lainen MH, Karlsson R 2000. Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels. J Med Chem 43: 1986-1992.
80. Gardner MJ, Hall N, Fung E, White O, Berriman M, HymanRW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan MS, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DMA, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM, Subramanian GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B 2002. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419: 498-511.
81. Ginsburg H 1999. Iron acquisition by Plasmodium spp. Parasitol Today 15: 466.
82. Ginsburg H, Famin O, Zhang J, Krugliak M 1998. Inhibition of glutathione-dependent degradation of heme by chloroquine and amodiaquine as a possible basis for their antimalaria mode of action. Biochem Pharmacol 56: 1305-1313.
83. Ginsburg H, Golenser J 2003. Glutathione is involved in the antimalarial action of chloroquine and its modulation affects drug sensitivity of human and murine species of Plasmodium. Redox Rep 8: 276-279.
84. Glickman MS, Jacobs Jr WR 2001. Microbial pathogenesis of Mycobacterium tuberculosis: dawn of a discipline. Cell 104: 477-485.
85. Gomez JE, McKinney JD 2004. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis 84: 29-44.
86. Gordeuk VR, Thuma PE, Brittenham GM, Zulu S, Simwanza G, Mhangu A, Flesch G, Parry D 1992. Iron chelation with desferrioxamine B in adults with asymptomatic Plasmodium falciparum parasitemia. Blood 79: 308-312.
87. Gornick P 2003. Apicoplast fatty acid biosynthesis as a target for medical intervention in apicomplexsan parasites. Int J Parasitol 33: 885-896.
88. Gregianini TS, Silveira VC, Porto DD, Kerber VA, Henriques AT, Fett-Neto AG 2003. The alkaloid brachycerine is induced by ultraviolet radiation and is a singlet oxygen quencher. Photochem Photobiol 78: 470-474.
89. Guida WC, Elliot RD, Thomas HJ, Secrist JAIII, Babu YS, Bugg CE, Erion MD, Ealick SE, Montgomery JA 1994. Structure-based design of inhibitors ofpurine nucleoside phosphorylase. 4. A study of phosphate mimics. J Med Chem 37: 1109-1114.
90. Gunasekera SP, Gunasekera M, Longley RE, Schulte GK 1990. Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge Discodermia dissoluta. J Org Chem 55: 4912-4915.
91. Gunasekera SP, Mickel SJ, Daeffler R, Niederer D, Wright AE, Linley P, Pitts T 2004. Synthetic analogues of the microtubule-stabilizing agent (+)-discodermolide: preparation and biological activity. J Nat Prod 67: 749-756.
92. Harborne JB, Baxter H 1993. Phytochemical Dictionary: a Handbook of Bioactive Compounds from Plants, Taylor and Francis, London.
93. Haynes R 2001. Artemisinin and derivatives: the future for malaria treatment? Curr Opin Infect Dis 14: 719-726.
94. Heifets LB 1994. Antimycobacterial drugs. Semin Respir Infect 9: 84-103
95. Hermanson GT 1966. Bioconjugate Techniques, Academic Press, San Diego, p. 137-168.
96. Herrmann KM, Weaver LM 1999. The shikimate pathway. Annu Rev Plant Physiol Mol Biol 50: 473-503.
97. Hershko C, Theanacho EN, Spira DT, Peter HH, Dobbin P, Hider RC 1991. The effect of N-alkyl modification on the antimalarial activity of 3-hydroxypyridin-4-one oral iron chelators. Blood 77: 637-643.
98. Heym B, Alzari PM, Honoré N, Cole ST 1995. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol 15: 235-245.
99. Hingley-Wilson SM, Sambandamurthy VK, Jacobs Jr WR 2003. Survival perspectives from the world's most successful pathogen, Mycobacterium tuberculosis. Nat Immunol 4: 949-955.
100. Hommais F, Krin E, Laurent-Wintr C, Soutorina O, Malpertuy A, Le Caer JP, Danchin A, Bertin P 2001. Large-scale monitoring of pleiotropic regulation of gene expression by the prokaryotic nucleoid-associated protein, H-NS. Mol Microbiol 40: 20-36.
101. Jennewein S, Croteau R 2001. Taxol: biosynthesis, molecular genetics and biotechnological applications. Appl Microbiol Biotechnol 57: 13-19.
102. Jimenez-Arellanes A, Meckes M, Ramirez R, Torres J, Luna-Herrera J 2003. Activity against multidrug-resistant Mycobacterium tuberculosis in Mexican plants. Phytother Res 17: 903-908.
103. Johnsson K, King DS, Schultz PG 1995. Studies on the mechanism of action of isoniazid and ethionamide in the chemotherapy of tuberculosis. J Am Chem Soc 117: 5009-5010.
104. Johnsson K, Schultz PG 1994. Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosis. J Am Chem Soc 116: 7425-7426.
105. Kalckar HM 1947. Differential spectrophotometry of purine compounds by means of specific enzymes: I. Determination of hydroxypurines. J Biol Chem 167: 429-443.
106. Kapoor M, Reddy CC, Krishnasastry MV, Surolia N, Surolia A 2004. Slow-tight-binding inhibition of enoyl-acyl carrier protein reductase from Plasmodium falciparum by triclosan. Biochem J 381: 719-724.
107. Kappe SHI, Kaiser K, Matuschewski K 2003. The Plasmodium sporozoite journey: a rite of passage. Trends Parasitol 19: 135-143.
108. Karlsson R, Kullman-Magnusson M, Hama MD, Remaeus A, Andersson K, Borg P, Gyzander E, Deinum J 2000. Biosensor analysis of drug-target interactions: direct and competitive binding assays for investigation of interactions between thrombin and thrombin inhibitors. Anal Biochem 278: 1-13.
109. Kazmers IS, Mitchell BS, DaDonna PE, Wotring II, Towsend LB, Kelly WN 1981. Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: selective tocxicity for T-lymphocytes. Science 214: 1137-1139.
110. Kicsca GA, Long L, Hörig H, Fairchild G, Tyler PC, Furneaux RH, Schramm VL, Kaufman HL 2001. Immucillin-H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. Proc Natl Acad Sci USA 98: 4593-4598.
111. Kicska GA, Tyler PC, Evans GB, Furneaux RH, Kim K, Schramm VL 2002b. Transition state analogue inhibitors of purine nucleoside phosphorylase from Plasmodium falciparum. J Biol Chem 277: 3219-3225.
112. Kicska GA, Tyler PC, Evans GB, Furneaux RH, Schramm VL, Kim K 2002a. Purine-less death in Plasmodium falciparum induced by immucillin-H, a transition state analogue of purine nucleoside phosphorylase. J Biol Chem 277: 3226-3231.
113. Kirkpatrick P 2002. Antibacterial drugs: stitching together naturally. Nature Rev Drug Discov 1: 748.
114. Kissau L, Stahl P, Mazitschek R, Giannis A, Waldmann H 2003. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold. J Med Chem 46: 2917-2931.
115. Kline PC, Schramm VL 1993. Purine nucleoside phosphorylase. Catalytic mechanism and transition-state analysis of the arsenolysis reaction. Biochemistry 32: 13212-13219.
116. Ko E, Park JW, Rho S, Cho C, Park S, Ko S, Lee Y, Hong MC, Shin MK, Ryu KW, Bae H 2004. Chung-Yeul-Gue-Soup-Sa-Gan-Tang, traditional Korean medicine, enhances CD4(+) T cell activities and modulates Th1;Th2 lineage development. J Pharmacol Sci. 94: 359-367.
117. Koehn FE, Carter GT 2005. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4: 206-220.
118. Kremer L, Dover LG, Morbidoni HR, Vilchèze C, Maughan WN, Baulard A, Tu S-C, Honoré N, Deretic V, Sacchettini JC, Locht C, Jacobs WRJr, Besra GS 2003. Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria. J Biol Chem 278: 20547-20554.
119. Kuntz ID, Meng EC, Shoichet BK 1994. Structure-based drug design. Accounts Chem Res 27: 117-123.
120. Kushner S, Dalalian H, Sanjurjo JL, Bach FL, Safir SR, Smith Jr VK, Williams JH 1952 Experimental chemotherapy of tuberculosis. The synthesis of pyrazinamides and related compounds. J Am Chem Soc 74: 3617-3621.
121. Kutchan T 1995. Alkaloid biosynthesis - The molecular basis for metabolic engineering in plants. Plant Cell 7: 1059-1070.
122. Larsen MH, Vilchèze C, Kremer L, Besra GS, Parsons L, Salfinger M, Heifets L, Hazbon MH, Alland D, Sacchettini JC, Jacobs Jr WR 2002. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol Microbiol 46: 453-466.
123. Lee ML, Schneider G 2001. Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries. J Comb Chem 3: 284-289.
124. Lei B, Wei C-J, Tu S-C 2000. Action mechanism of antitubercular isoniazid. J Biol Chem 275: 2520-2526.
125. Levinson W, Jawetz E 2000. Medical Microbiology and Immunology, Lange Medical Books/McGraw-Hill, New York, p. 344-363.
126. Lewis WH, Elvin-Lewis MP 1995. Medicinal plants as sources of new therapeutics. Ann Missouri Bot Gard 82: 16-24.
127. Ley SV, Baxendale IR 2002. New tools and concepts for modern organic synthesis. Nature Rev Drug Discov 1: 573-586.
128. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 23: 3-25.
129. Marrakchi H, Ducasse S, Labesse G, Montrozier H, Margeat E, Emorine L, Charpentier X, Daffé M, Quémard A 2002. MabA (FabG1), a Mycobacterium tuberculosis protein involved in the long-chain fatty acid elongation system FAS-11. Microbiology 148: 951-960.
130. Marshall JA, Johns BA 1998. Total synthesis of (+)-Discodermolide. J Org Chem 63: 7885-7892.
131. Martin YC, Critchlow RE 1999. Beyond mere diversity: tailoring combinatorial libraries for drug discovery. J Com Chem 1: 231-250.
132. Matos JMD, Matos MEO 1989. Farmacognosia. Curso Teórico- Prático. UFCE, Fortaleza.
133. McConkey GA 1999. Targeting the shikimate pathway in the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother 43: 175-177.
134. McConkey GA, Pinney JW, Westhead DR, Plueckhahn K, Fitzpatrick TB, Macheroux, Kappes B 2003. Annotating the Plasmodium genome and the enigma of the shikimate pathway. Trends Parasitol 20: 60-65.
135. McKinney JD, Jacobs Jr WR, Bloom BR 1998. Persisting problems in tuberculosis. In RM Krause, Emerging Infections. Academic Press, New York, p. 51-146.
136. McLeod R, Muench SP, Rafferty JB, Kyle DE, Mui EJ, Kirisits MJ, Mack DG, Roberts CW, Samuel BU, Lyons RE, Dorris M, Milhous WK, Rice DW 2001. Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of Apicomplexan Fab I. Int J Parasitol 31: 109-113.
137. McRee DE 1999. XtalView/Xfit-A versatile program for manipulating atomic coordinates and electron density. J Struct Biol 125: 156-65.
138. McRobert L, McConkey GA 2002. RNA interference (RNAi) inhibits growth of Plasmodium falciparum. Mol Biochem Parasitol 119: 273-278.
139. Mdluli K, Slayden RA, Zhu Y, Ramaswamy S, Pan X, Mead D, Crane DD, Musser JM, Barry CEIII 1998. Inhibition of Mycobacterium tuberculosis b-ketoacyl ACP synthase by isoniazid. Science 280: 1607-1610.
140. Middlebrook G 1952. Sterilization of tubercle bacilli by isonicotinic acid hydrazide and the incidence of variants resistant to the drug in vitro. Am Rev Tuberc 65: 765-767.
141. Miles RW, Tyler PC, Furneaux RH, Bagdassarian CK, Schramm VL 1998. One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry 37: 8615-8621.
142. Mitchell BS, Mejias E, DaDonna PE, Kelley WN 1978. Purinogenic immunodeficienty diseases: selective toxicity of deoxyribonucleosides for T-cells. Proc Natl Acad Sci USA 75: 5011-5014.
143. Mitchison DA 1985. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66: 219-225.
144. Mitchison DA 2005. Shortening the treatment of tuberculosis. Nat Biotechnol 23: 187-188.
145. Morens DM, Folkers GK, Fauci AS 2004. The challenge of emerging and re-emerging infectious diseases. Nature 430: 242-248.
146. Morris PE, Elliott AJ, Walton SP, Williams CH, Montgomery JA 2000. Synthesis and biological activity of a novel class of purine nucleoside phosphorylase inhibitors. Nucleosides, Nucleotides & Nucleic Acids 19: 379-404.
147. Morrison JF, Walsh CT 1988. The behaviour and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 61: 201-301.
148. Morsczeck C 2003. Strategies for mycobacterial genetics. Int J Med Microbiol 293: 251-259.
149. Mousdale DM, Coggins JR 1985. High-performance liquid chromatography of shikimate pathway intermediates. J Chromatogr 329: 268-272.
150. Myers N, Mittermeler RA, Mittermeler CG, Fonseca GAB, Kent J 2000. Biodiversity hotspots for conservation priorities. Nature 403: 853-858.
151. Navaza J 1994. AMoRe: an automated package for molecular replacement. Acta Crystallogr A50: 157-163.
152. Newman DJ, Cragg GM, Snader KM 2000. The influence of natural products upon drug discovery. Nat Prod Rep 17: 215-234.
153. Newman DJ, Cragg GM, Snader KM 2003. Natural products as a source of new drugs over the period 1981-2002. J Nat Prod 66: 1022-1237.
154. Nienaber VL, Richardson PL, Klighofer V, Bouska JJ, Giranda VL, Greer J 2000. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat Biotechnol 18: 1105-1108.
155. Niggemann J, Michaelis K, Frank K, Zander N, Höfle G 2002. Natural product-derived building blocks for combinatorial synthesis. Part 1. Fragmentation of natural products from myxobacteria. J Chem Soc Perkin Trans 1: 2490-2503.
156. Nishino K, Yamaguchi A 2004. Role of histone-like protein H-NS in multidrug resistance of Escherichia coli. J Bacteriol 186: 1423-1429.
157. Nolasco DO, Canduri F, Pereira JH, Cortinoz JR, Palma MS, Oliveira JS, Basso LA, Azevedo Jr WF, Santos DS 2004. Crystallographic structure of PNP from Mycobacterium tuberculosis at 1.9 Å resolution. Biochem Biophys Res Commun 324: 789-794.
158. Nundkumar N, Ojewole JA 2002. Studies on the antiplasmodial properties of some South African medicinal plants used as antimalarial remedies in Zulu folk medicine. Methods Find Exp Clin Pharmacol 24: 397-401.
159. Nunn P 1997. WHO Global TB Programme, Tuberculosis Research and Surveillance Unit of the WHO Global TB Programme; Press Release WHO/74 (www.who.int/gtb/ press/who74.htm).
160. Nye MB, Pfau JD, Skorupski K, Taylor RK 2000. Vibrio cholerae H-NS silences virulence gene expression at multiple steps in the ToxR regulatory casdade. J Bacteriol 182: 4295-4303.
161. O'Brien RJ, Nunn PP 2001. The need for new drugs against tuberculosis. Am J Respir Crit Care Med 162: 1055-1058.
162. O'Neill P, Bray P, Hawley S, Ward S, Park B 1998. 4-Aminoquinolines - past, present, and future: a chemical perspective. Pharmacol Ther 77: 29-58.
163. Ojha AK, Muckherjee TK, Chatterji D 2000. High intracellular level of guanosine tetraphosphate in Mycobacterium smegmatis changes the morphology of the bacterium. Infect Immun 68: 4084-4091.
164. Okello EJ, Savelev SU, Perry EK 2004. In vitro anti-beta-secretase and dual anti-cholinesterase activities of Camellia sinensis L. (tea) relevant to treatment of dementia. Phytother Res 18: 624-627.
165. Oksman-Caldentey KM, Inzé D 2004. Plant cell factories in the post-genomic era: new ways to produce designer secondary metabolites. Trends Plant Sci 9: 433-440.
166. Oliveira JS, Mendes MA, Palma MS, Basso LA, Santos DS 2003. One-step purification of 5-enolpyruvylshikimate-3-phosphate synthase enzyme from Mycobacterium tuberculosis. Protein Expr Purif 28: 287-92.
167. Oliveira JS, Pinto CA, Basso LA, Santos DS 2001. Cloning and overexpression in soluble form of functional shikimate kinase and 5-enolpyruvylshikimate 3-phosphate synthase enzymes from Mycobacterium tuberculosis. Protein Expr Purif 22: 430-435.
168. Oliveira JS, Sousa EHS, Basso LA, Palaci M, Dietze R, Santos DS, Moreira IS 2004. An inorganic iron complex that inhibits wild-type and an isoniazid-resistant mutant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis. Chem Commun 3: 312-313.
169. Oliveira JS, Sousa EHS, de Souza ON, Moreira, IS, Santos DS, Basso LA 2005. Slow-onset inhibition by an inorganic complex of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis. Curr Pharm Des (in press).
170. Owen-Hughes TA, Pavitt GD, Santos DS, Sidebotham JM, Hulton CSJ, Hinton JCD, Higgins CF 1992. The chromatin-associated protein H-NS interacts with curved DNA and influence DNA topology and gene expression. Cell 71: 255-265.
171. Pablos-Méndez A, Gowda DK, Frieden TR 2002. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Bull WHO 80: 489-495.
172. Paranhos JT, Fragoso V, Henriques AT, Ferreira AG, Fett-Neto AG 2005. Regeneration of Psychotria umbellata and production of the analgesic indole alkaloid umbellatine. Tree Physiol 25: 251-255.
173. Parish T, Stoker NG 2002. The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis. Microbiology 148: 3069-3077.
174. Parish T, Lewis J, Stoker NG 2001. Use of the mycobacteriophage L5 excisionase in Mycobacterium tuberculosis to demonstrate gene essentiality. Tuberculosis 81: 359-364.
175. Parks Jr RE, Agarwal RP 1972. Purine nucleoside phosphorylase. The enzymes 7: 483-514.
176. Paterson I, Florence GJ, Gerlach K, Scott JP 2000. Total synthesis of the antimicrotubule agent (+)-Discodermolide using boron-mediated aldol reactions of chiral ketones. Angew Chem Int Ed 39: 377.
177. Pereira JH, Canduri F, Oliveira JS, Silveira NJF, Basso LA, Palma MS, Azevedo Jr WF, Santos DS 2003. Structural bioinformatics study of EPSP synthase from Mycobacterium tuberculosis. Biochem Biophys Res Commun 312: 608-614.
178. Pereira JH, Oliveira JS, Canduri F, Dias MVB, Palma MS, Basso LA, Santos DS, Azevedo Jr WF 2004a. Structure of shikimate kinase from Mycobacterium tuberculosis reveals the binding of shikimic acid. Acta Crystallogr D Biol Crystallogr 6: 2310-2319.
179. Pereira JH, Oliveira JS, Canduri F, Dias MVB, Palma MS, Basso LA, Santos DS, Azevedo Jr WF 2004b. Interaction of shikimic acid with shikimate kinase. Biochem Biophys Res Commun 325: 10-17.
180. Perozzo R, Kuo M, Sidhu ABS, Valiyaveettil JT, Bittman R, Jacobs Jr WR, Fidock DA, Sacchettini JC 2002. Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase. J Biol Chem 277: 13106-13114.
181. Piehler J 2005. New methodologies for measuring protein interactions in vivo and in vitro. Curr Opin in Struct Biol 15: 4-14.
182. Pierattelli R, Banci L, Eady NAJ, Bodiguel J, Jones JN, Moody PCE, Raven EL, Jamart-Grégoire B, Brown KA 2004. Enzyme-catalyzed mechanism of isoniazid activation in Class I and Class III peroxidases. J Biol Chem 279: 39000-39009.
183. Pillai S, Rajagopal C, Kapoor M, Kumar G, Gupta A, Surolia N 2003. Biochem Biophys Res Commun 303: 387-392.
184. Porter DJ 1992. Purine nucleoside phosphorylase. Kinetic mechanism of the enzyme from calf spleen. J Biol Chem 297: 7342-7351.
185. Pradines B, Rolain JM, Ramiandrasoa F, Fusai T, Mosnier J, Rogier C, Daries W, Baret E, Kunesch G, Le Bras, J, Parzy D 2002. Iron chelators as antimalarial agents: in vitro activity of dicatecholate against Plasmodium falciparum. J Antimicrob Chemother 50: 177-187.
186. Primm TP, Andersen SJ, Mizrahi V, Avarbock D, Rubin H, Barry CBIII 2000. The stringent response of Mycobacterium tuberculosis is required for long-term survival. J Bacteriol 182: 4889-4898.
187. Pugmire MJ, Ealick SE 2002. Structural analyses reveal two distinct families of nucleoside phosphorylases. Biochem J 361: 1-25.
188. Quémard A, Sacchettini JC, Dessen A, Vilchèze C, Bittman R, Jacobs Jr WR, Blanchard JS 1995. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 34: 8235-8241.
189. Ramaswamy S, Musser JM 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis. 79: 3-29.
190. Ramaswamy SV, Reich R, Dou S-J, Jasperse L, Pan X, Wanger A, Quitugua T, Graviss EA 2003. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 47: 1241-1250.
191. Raskin I, Ribnicky DM, Komamytsky S, Ilic N, Poulsy A, Borisjuk N, Brinker A, Moreno DA, Ripoll C, Yakoby N, O'Neal JM, Cornwell T, Pastor I, Fridlender B 2002. Plants and human health in the twenty-first century. Trends Biotechnol 20: 522-531.
192. Rates SMK 2001. Plants as source of drugs. Toxicon 39: 603-613.
193. Raviglione MC 2003. The TB epidemic from 1992 to 2002. Tuberculosis 83: 4-14.
194. Rawat R, Whitty A, Tonge PJ 2003. The isonizid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance. Proc Natl Acad Sci USA 100: 13881-13886.
195. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M 1998. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol 13: 893-906.
196. Reyes P, Rathod PK, Sanchez DJ, Mrema JE, Rieckmann KH, Heidrich HG 1982. Enzymes of purine and pyrimidine metabolism from the human malaria parasite, Plasmodium falciparum. Mol Biochem Parasitol 5: 275-290.
197. Ridley RG 2002. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 415: 686-693.
198. Rizzi C, Frazzon J, Ely F, Weber PG, Fonseca IO, Gallas M, Oliveira JS, Mendes MA, Souza BM, Palma MS, Santos DS, Basso LA 2005. DAHP synthase from Mycobacterium tuberculosis H37Rv: cloning, expression, and purification of functional enzyme. Protein Expr Purif 40: 23-30.
199. Roberts F, Roberts CW, Johnson JJ, Kyle DE, Krell T, Coggins JR, Coombs GH, Milhous WK, Tzipori S, Fergunson DJP, Chakrebarti D, McLeod R 1998. Evidence for shikimate pathway in apicomplexan parasites. Nature 393: 801-805.
200. Rotheneder A, Fritsche G, Heinisch L, Mollmann U, Heggemann S, Larcher C, Weiss G 2002. Effects of synthetic siderophores on proliferation of Plasmodium falciparum in infected human erythrocytes. Antimicrob Agents Chemother 46: 2010-2013.
201. Rozwarski DA, Grant GA, Barton DHR, Jacobs Jr WR, Sacchettini JC 1998. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279: 98-102.
202. Santos DM, Canduri F, Pereira JH, Dias MVB, Silva RG, Mendes MA, Palma MS, Basso LA, Azevedo Jr WF, Santos DS 2003. Crystal structure of human purine nucleoside phosphorylase complexed with acyclovir. Biochem Biophys Res Commun 308: 553-559.
203. Schatz A, Bugie E, Waksman SA 1944. Streptomycin, a substrate exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Proc Soc Exp Biol Med 55: 66.
204. Schloss JV 1988. Significance of slow-binding enzyme inhibition and its relationship to reaction-intermediate analogues. Acc Chem Res 21: 348-353.
205. Schramm VL 1998. Enzymatic transition states and transition state analog design. Annu Rev Biochem 67: 693-720.
206. Schramm VL 2002. Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents. Biochim Biophys Acta 1578: 107-117.
207. Schramm VL 2005. Enzymatic transition states: thermodynamics, dynamics and analogue design. Arch Biochem Biophys 433: 13-26.
208. Schroeder EK, Basso LA, Santos DS, de Souza ON 2005. Molecular dynamics simulation studies of the wild-type, I21V and I16T mutants of isoniazid resistant Mycobacterium tuberculosis enoyl reductase (InhA) in complex with NADH: towards the understanding of NADH-InhA different affinities. Biophys J 89: 1-9.
209. Schroeder EK, de Souza ON, Santos DS, Blanchard JS, Basso LA 2002. Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis. Curr Pharm Biotechnol 3: 197-225.
210. Scott B 2001. Epichloe endophytes: fungal symbionts of grasses. Curr Op Microbiol 4: 393-398.
211. Seeber F 2003. Biosynthetic pathways of plastid-derived organelles as potential drug targets against parasitic apicomplexa. Curr Drug Targets Immune Endocr Metabol Disord 3: 99-109.
212. Service RF 2004. Surviving the blockbuster syndrome. Science 303: 1796-1799.
213. Shaw MK 2003. Cell invasion by Theileria soporozoites. Trends Parasitol 19: 2-6.
214. Sherman IW 1979. Biochemistry of Plasmodium (malarial parasites). Microbiol Rev 43: 453-495.
215. Shi W, Basso LA, Santos DS, Tyler PC, Furneaux RH, Blanchard JS, Almo SC, Schramm VL 2001. Structures of purine nucleoside phosphorylase from Mycobacterium tuberculosis in complexes with Immucillin-H and its pieces. Biochemistry 40: 8204-15.
216. Shi W, Ting LM, Kicska GA, Lewandowicz A, Tyler PC, Evans GB, Furneaux RH, Kim K, Almo SC, Schramm VL 2004. Plasmodium falciparum purine nucleoside phosphorylase. Crystal structures, Immucillin inhibitors and dual catalytic function. J Biol Chem 279: 18103-18106.
217. Shirley MW, Ivens A, Gruber A, Madeira AMBN, Wan KL, Dear PH, Tomley FM 2004. The Eimeria genome projects: a sequence of events. Trends Parasitol 20: 199-201.
218. Silva RG, Carvalho LPS, Oliveira JS, Pinto CA, Mendes MA, Palma MS, Basso LA, Santos DS 2003. Cloning, overexpression, and purification of functional human purine nucleoside phosphorylase. Protein Expr Purif 27: 158-164.
219. Sirawaraporn W 1998. Dihydrofolate reductase and antifolate resistance in malaria. Drug Resist Update 1: 397-406.
220. Slayden RA, Barry CEIII 2002. The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in Mycobacterium tuberculosis. Tuberculosis 82: 149-160.
221. Smith I 2003. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev 16: 463-496.
222. Smith AB, Cho YS, Pettit GR, Hirschmann R 2003. Design, synthesis, and evaluation of azepine-based cryptophycin mimetics. Tetrahedron 59: 6991-7009.
223. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434: 214-217.
224. Soares MBP, Bellintani MC, Ribeiro IM, Tomassini TCB, Ribeiro dos Santos R 2003. Inhibition of macrophage activation and lipopolysaccaride-induced death by seco-steroids purified from Physalis angulata L. Eur J Pharmacol 459: 107-112.
225. Stahlhut R, Park G, Petersen R, Ma WW, Hylands P 1999. The occurrence of the anti-cancer diterpene taxol in Podocarpus gracilior Pilger (Podocarpaceae). Biochemical Systematics and Ecol 27: 613-622.
226. Stahura F, Godden JW, Ling X, Bajorath J 2000. Distinguishing between natural products and synthetic molecules by descriptor Shannon entropy analysis and binary QSAR calculations. J Chem Inf Comput Sci 40: 1245-1252.
227. Steinrücken HC, Amrhein N 1980. The herbicide glyphosate is a potent inhibitor of 5-enol pyruvyl shikimic acid-3-phosphate synthase. Biochem Biophys Res Comm 94: 1207-1212.
228. Stoeckler JD, Cambor C, Parks Jr RE 1980. Human erythrocytic purine nucleoside phosphorylase: reaction with sugar-modified nucleosides substrates. Biochemistry 19: 102-107.
229. Stoop JW, Zegers BJM, Hendrick GFM, van Heukelom LHS, Staal GEJ, DeBree PK, Wadman SK, Ballieux RE 1977. Purine nucleoside phosphorylase deficienty associated with selective cellular immunodeficienty. N Engl J Med 296: 2522-2527.
230. Surolia N, Surolia A 2001. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase ofPlasmodium falciparum. Nat Med 7: 167-173.
231. Thabrew MI, Senaratna L, Samarawickrema N, Musasingue C 2001. Antioxidant potential of two polyherbal preparations used in Ayurveda for the treatment of rheumatoid arthritis. J Ethnopharmacol 76: 285-291.
232. Ting LM, Shi W, Lewandowicz A, Singh V, Mwakingwe A, Birck MR, Ringia EAT, Bench G, Madrid DC, Tyler PC, Evans GB, Furneaux RH, Schramm VL, Kim K 2005. Targeting a novel Plasmodium falciparum purine recycling pathway with specific immucillins. J Biol Chem 280: 9547-9554
233. Tosun F, Kizilay CA, Sener B, Vural M, Palittapongampim P 2004. Antimycobacterial screening of some Turkish plants. J Ethnopharmacol 95: 273-275.
234. Tran QL, Tezuka Y, Ueda JY, Nguyen NT, Maruyama Y, Begum K, Kim HS, Wataya Y, Tran QK, Kadota S 2003. In vitro antiplasmodial activity of antimalarial medicinal plants used in Vietnamese traditional medicine. J Ethnopharmacol 86: 249-252.
235. Van der Heijden MGA, Klironomos JN, Ursic M, Moutoglis P, Streitwolf-Engle R, Boller T, Wiemken, Sanders IR 1998. Mycorrhizal fungal diversity determines plant diversity, ecosystem variability and productivity. Nature 396: 69-72.
236. Vieth M, Siegel MG, Higgs RE, Watson IA, Robertson DH, Savin KA, Durst GL, Hipskind PA 2004. Characteristic physical properties and structural fragments of marketed oral drugs. J Med Chem 47: 224-232.
237. Vilchèze C, Morbidoni HR, Weisbrod TR, Iwamoto H, Kuo M, Sacchettini JC, Jacobs Jr WR 2000. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J Bacteriol 182: 4059-4067.
238. Watanabe M, Aoyagi Y, Mitome H, Fujita T, Naoki H, Ridell M, Minnikin DE 2002. Location of functional groups in mycobacterial meromycolate chains; the recognition of new structural principles in mycolic acids. Microbiology 14: 1881-1902.
239. Wellems T, Plowe C 2001. Chloroquine-resistant malaria. J Infect Dis 184: 770-776.
240. Wiesmann WP, Webster HK, Lambros C, Kelley WN, Daddona PE 1984. Adenosine deaminase in malaria infected erythrocytes: unique parasite enzyme presents a new therapeutic target. Prog Clin Biol Res 165: 325-342.
241. Wink M 2003. Evolution of secondary metabolites from an ecological and molecular phylogenetic perspective. Phytochemistry 64: 3-19.
242. Woo PWK, Kostlan CR, Sircar JC, Dong MK, Gilbertsen RB 1992. Inhibitors of human purine nucleoside phosphorylase. Synthesis and biological activities of 8-amino-3-benzylhypoxanthine and related analogues. J Med Chem 35: 1451-1457.
243. WHO-World Health Organization 2004. Anti-tuberculosis drug resistance in the world: Third Global Report, Geneve.
244. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM 2005. Curcumin inhibits formation of amyloid-b oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280: 5892-5901.
245. Yu S, Girotto S, Lee C, Magliozzo RS 2003. Reduced affinity for isoniazid in the S315T mutant of Mycobacterium tuberculosis KatG is a key factor in antibiotic resistance. J Biol Chem 278: 14769-14775.
246. Zabinski RF, Blanchard JS 1997. The requirement for manganese and oxygen in the isoniazid-dependent inactivation of Mycobacterium tuberculosis enoyl reductase. J Am Chem Soc 119: 2331-2332.